Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice
Published: octubre 07, 2024
- Lipoprotein apheresis (LA) is a Food and Drug Administration (FDA) approved adjunctive therapeutic option for treating refractory high levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a), in children and adults with clinical heterozygous and homozygous familial hypercholesterolemia who meet the criteria.
- Treatment with LA may acutely lower LDL-C concentration by 75-85%.
- Prospective and retrospective observational data suggest that LA may lower major adverse cardiovascular events by 75-95%. Randomized controlled trials or larger prospective studies are warranted to further substantiate cardiovascular benefits.